Literature DB >> 14609817

Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I.

Kai C Wollert1, Sevdalina Yurukova, Ana Kilic, Frank Begrow, Beate Fiedler, Stepan Gambaryan, Ulrich Walter, Suzanne M Lohmann, Michaela Kuhn.   

Abstract

1. C-type natriuretic peptide (CNP) and its receptor guanylyl cyclase (GC-B) are expressed in the heart and modulate cardiac contractility in a cGMP-dependent manner. Since the distal cellular signalling pathways remain unclear, we evaluated the peptide effects on cardiac function and calcium regulation in wild-type (WT) and transgenic mice with cardiac overexpression of cGMP-dependent protein kinase I (PKG ITG). 2. In isolated, perfused working WT hearts, CNP (10 nm) provoked an immediate increase in the maximal rates of contraction and relaxation, a small increase in the left ventricular systolic pressure and a decrease in the time of relaxation. These changes in cardiac function were accompanied by a marked increase in the levels of Ser16-phosphorylated phospholamban (PLB). 3. In PKG ITG hearts, the effects of CNP on cardiac contractility and relaxation as well as on PLB phosphorylation were markedly enhanced. 4. CNP increased cell shortening and systolic Cai2+ levels, and accelerated Cai2+ decay in isolated, Indo-1/AM-loaded WT cardiomyocytes, and these effects were enhanced in PKG I-overexpressing cardiomyocytes. 5. 8-pCPT-cGMP, a membrane-permeable PKG activator, mimicked the contractile and molecular actions of CNP, the effects again being more pronounced in PKG ITG hearts. In contrast, the cardiac responses to beta-adrenergic stimulation were not different between genotypes. 6. Taken together, our data indicate that PKG I is a downstream target activated by the CNP/GC-B/cGMP-signalling pathway in cardiac myocytes. cGMP/PKG I-stimulated phosphorylation of PLB and subsequent activation of the sarcoplasmic reticulum Ca2+ pump appear to mediate the positive inotropic and lusitropic responses to CNP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609817      PMCID: PMC1574150          DOI: 10.1038/sj.bjp.0705567

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  The guanylyl cyclase receptors.

Authors:  D L Garbers
Journal:  Methods       Date:  1999-12       Impact factor: 3.608

2.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms.

Authors:  Lili A Barouch; Robert W Harrison; Michel W Skaf; Gisele O Rosas; Thomas P Cappola; Zoulficar A Kobeissi; Ion A Hobai; Christopher A Lemmon; Arthur L Burnett; Brian O'Rourke; E Rene Rodriguez; Paul L Huang; João A C Lima; Dan E Berkowitz; Joshua M Hare
Journal:  Nature       Date:  2002-03-21       Impact factor: 49.962

3.  Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice.

Authors:  M Kuhn; R Holtwick; H A Baba; J C Perriard; W Schmitz; E Ehler
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

4.  Cardiac fibrosis in mice lacking brain natriuretic peptide.

Authors:  N Tamura; Y Ogawa; H Chusho; K Nakamura; K Nakao; M Suda; M Kasahara; R Hashimoto; G Katsuura; M Mukoyama; H Itoh; Y Saito; I Tanaka; H Otani; M Katsuki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 5.  The physiological and pathophysiological modulation of the endocrine function of the heart.

Authors:  A J de Bold; K K Ma; Y Zhang; M L de Bold; M Bensimon; A Khoshbaten
Journal:  Can J Physiol Pharmacol       Date:  2001-08       Impact factor: 2.273

6.  Mechanisms of NO/cGMP-dependent vasorelaxation.

Authors:  M Sausbier; R Schubert; V Voigt; C Hirneiss; A Pfeifer; M Korth; T Kleppisch; P Ruth; F Hofmann
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

7.  Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes.

Authors:  Kai C Wollert; Beate Fiedler; Stepan Gambaryan; Albert Smolenski; Jörg Heineke; Elke Butt; Christian Trautwein; Suzanne M Lohmann; Helmut Drexler
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

8.  cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium.

Authors:  Jörg W Wegener; Hermann Nawrath; Wiebke Wolfsgruber; Susanne Kühbandner; Claudia Werner; Franz Hofmann; Robert Feil
Journal:  Circ Res       Date:  2002-01-11       Impact factor: 17.367

9.  Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1.

Authors:  U Kirchhefer; J Neumann; H A Baba; F Begrow; Y M Kobayashi; U Reinke; W Schmitz; L R Jones
Journal:  J Biol Chem       Date:  2000-11-07       Impact factor: 5.157

10.  Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes.

Authors:  G Vandecasteele; I Verde; C Rücker-Martin; P Donzeau-Gouge; R Fischmeister
Journal:  J Physiol       Date:  2001-06-01       Impact factor: 5.182

View more
  16 in total

1.  Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.

Authors:  Kalkidan Bishu; Nazha Hamdani; Selma F Mohammed; Martina Kruger; Tomohito Ohtani; Ozgur Ogut; Frank V Brozovich; John C Burnett; Wolfgang A Linke; Margaret M Redfield
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

2.  Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium.

Authors:  S Weninger; J H De Maeyer; R A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-03-17       Impact factor: 3.000

3.  SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium.

Authors:  L R Moltzau; J M Aronsen; S Meier; C H T Nguyen; K Hougen; Ø Ørstavik; I Sjaastad; G Christensen; T Skomedal; J-B Osnes; F O Levy; E Qvigstad
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 4.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

Review 5.  Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart.

Authors:  Akihiro Yasoda
Journal:  Biology (Basel)       Date:  2022-06-14

6.  Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Authors:  Walid Mokni; Thérèse Keravis; Nelly Etienne-Selloum; Alison Walter; Modou O Kane; Valérie B Schini-Kerth; Claire Lugnier
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

Review 7.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

8.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

Review 9.  Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.

Authors:  Ines Pagel-Langenickel; Jens Buttgereit; Michael Bader; Thomas H Langenickel
Journal:  J Mol Med (Berl)       Date:  2007-04-12       Impact factor: 4.599

10.  Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I.

Authors:  Stefan Frantz; Michael Klaiber; Hideo A Baba; Heike Oberwinkler; Katharina Völker; Birgit Gaβner; Barbara Bayer; Marco Abeβer; Kai Schuh; Robert Feil; Franz Hofmann; Michaela Kuhn
Journal:  Eur Heart J       Date:  2011-12-23       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.